Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brepocitinib
- Development stage
- Approved
- Lead developer
- Priovant Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Brepocitinib is an orally administered small-molecule dual inhibitor of tyrosine kinase 2 and Janus kinase 1 that suppresses cytokine signaling implicated in autoimmune inflammation, including type I interferon, interleukin-12, interleukin-23, and other JAK1-dependent pathways. It was discovered by Pfizer and subsequently developed by Priovant for severe autoimmune diseases. Brepocitinib is marketed in the United States as Lisraya for adults with dermatomyositis and has also been evaluated in non-infectious uveitis, systemic lupus erythematosus, inflammatory bowel disease, psoriatic disease, alopecia areata, vitiligo, hidradenitis suppurativa, and atopic dermatitis.
- Brand names
- Lisraya
- Other names
- brepocitinib
02
Targets
Beyond the preview
Go deeper on brepocitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brepocitinib.